SK369292A3 - Orally administerable drugs for the treatment of central dopamine deficiency conditions - Google Patents

Orally administerable drugs for the treatment of central dopamine deficiency conditions Download PDF

Info

Publication number
SK369292A3
SK369292A3 SK3692-92A SK369292A SK369292A3 SK 369292 A3 SK369292 A3 SK 369292A3 SK 369292 A SK369292 A SK 369292A SK 369292 A3 SK369292 A3 SK 369292A3
Authority
SK
Slovakia
Prior art keywords
saponified polyvinyl
polyvinyl alcohol
acetyl content
residual acetyl
levodopa
Prior art date
Application number
SK3692-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK278736B6 (sk
Inventor
Udo Wenzel
Gunther Weber
Jurgen Metzner
Alfred Darr
Sabine Freitag
Frank-Ulrich Flother
Frank-Michael Albert
Margit Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of SK278736B6 publication Critical patent/SK278736B6/sk
Publication of SK369292A3 publication Critical patent/SK369292A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK3692-92A 1991-01-23 1992-01-23 Orally administerable drugs for the treatment of central dopamine deficiency conditions SK369292A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
PCT/DE1992/000043 WO1992012710A1 (de) 1991-01-23 1992-01-23 Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustände

Publications (2)

Publication Number Publication Date
SK278736B6 SK278736B6 (sk) 1998-02-04
SK369292A3 true SK369292A3 (en) 1998-02-04

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3692-92A SK369292A3 (en) 1991-01-23 1992-01-23 Orally administerable drugs for the treatment of central dopamine deficiency conditions

Country Status (22)

Country Link
US (1) US5532274A (ja)
EP (1) EP0568577B1 (ja)
JP (1) JP3382940B2 (ja)
AT (1) ATE147264T1 (ja)
AU (1) AU658171B2 (ja)
BG (1) BG61677B1 (ja)
CA (1) CA2101164C (ja)
CZ (1) CZ280847B6 (ja)
DE (2) DE4101873C2 (ja)
DK (1) DK0568577T3 (ja)
EE (1) EE03016B1 (ja)
ES (1) ES2098496T3 (ja)
FI (1) FI101040B (ja)
GR (1) GR3022993T3 (ja)
LT (1) LT3659B (ja)
LV (1) LV11103B (ja)
NO (1) NO304638B1 (ja)
RO (1) RO114737B1 (ja)
RU (1) RU2114619C1 (ja)
SK (1) SK369292A3 (ja)
UA (1) UA27848C2 (ja)
WO (1) WO1992012710A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
DE60237294D1 (de) * 2001-09-28 2010-09-23 Mcneil Ppc Inc Pharmazeutische zusammensetzung auf fondantbasis
KR20050083750A (ko) * 2002-10-11 2005-08-26 디포메드 디벨롭먼트 리미티드 위-체류성 레보도파 전달 형태
WO2005023185A2 (en) 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
EP1863455A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of parkinson's disease
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
KR101752080B1 (ko) 2007-12-28 2017-06-28 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
JP6694564B1 (ja) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 結合剤
WO2020100933A1 (ja) * 2018-11-13 2020-05-22 日本酢ビ・ポバール株式会社 結合剤
EP3881838A4 (en) * 2018-11-13 2022-08-17 Japan Vam & Poval Co., Ltd. ADHESIVE
EP4134103A4 (en) * 2020-04-10 2024-04-24 Japan Vam & Poval Co., Ltd. BINDER
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
ES2052681T5 (es) * 1987-12-31 1997-12-01 Asta Medica Ag Combinacion sinergica de inhibidores de descarboxilasa y granulos de l-dopa.
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets

Also Published As

Publication number Publication date
WO1992012710A1 (de) 1992-08-06
AU1186892A (en) 1992-08-27
FI933304A (fi) 1993-07-22
AU658171B2 (en) 1995-04-06
CZ369292A3 (en) 1993-09-15
EP0568577A1 (de) 1993-11-10
CA2101164C (fr) 2001-04-24
ES2098496T3 (es) 1997-05-01
SK278736B6 (sk) 1998-02-04
UA27848C2 (uk) 2000-10-16
BG61677B1 (bg) 1998-03-31
NO932522L (no) 1993-07-09
LV11103B (en) 1996-06-20
JP3382940B2 (ja) 2003-03-04
DE59207852D1 (de) 1997-02-20
FI933304A0 (fi) 1993-07-22
DK0568577T3 (da) 1997-06-30
US5532274A (en) 1996-07-02
NO304638B1 (no) 1999-01-25
ATE147264T1 (de) 1997-01-15
LV11103A (lv) 1996-04-20
EP0568577B1 (de) 1997-01-08
BG97894A (bg) 1994-04-29
RO114737B1 (ro) 1999-07-30
EE03016B1 (et) 1997-08-15
LT3659B (en) 1996-01-25
JPH06504543A (ja) 1994-05-26
RU2114619C1 (ru) 1998-07-10
CZ280847B6 (cs) 1996-04-17
FI101040B (fi) 1998-04-15
LTIP555A (en) 1994-11-25
GR3022993T3 (en) 1997-07-30
CA2101164A1 (fr) 1992-07-24
DE4101873A1 (de) 1992-07-30
DE4101873C2 (de) 1993-12-09
NO932522D0 (no) 1993-07-09

Similar Documents

Publication Publication Date Title
SK369292A3 (en) Orally administerable drugs for the treatment of central dopamine deficiency conditions
CA2740146C (en) Immediate release dosage forms of sodium oxybate
EP1245232B1 (en) Oral solid preparation
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
KR101801424B1 (ko) 날부핀-기재 제제 및 그것의 용도
JPH10194969A (ja) 錠剤組成物
JPWO2002060446A1 (ja) ５−メチル−１−フェニル−２−（１ｈ）−ピリドンを有効成分として含有する医薬製剤
US5624960A (en) Orally administrable drugs for the treatment of central dopamine deficiency conditions
CA2874779A1 (en) Pharmaceutical composition of entecavir and process of manufacturing
WO2020109319A1 (en) Pharmaceutical composition comprising ramipril and indapamide
WO2009146608A1 (zh) 含有咪唑5-羧酸类衍生物的药用组合物，其制备方法及用途
KR101809886B1 (ko) 소형화된 클래리트로마이신 경구투여 제제
WO2020122244A1 (ja) 錠剤及びその製造方法
WO2014096983A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
EP2694039B1 (en) Solid preparation
WO2023128898A1 (en) Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
JP2022151841A (ja) ビルダグリプチン製剤
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
KR20200084649A (ko) 약학 조성물
CN116490178A (zh) Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
KR101125453B1 (ko) 엘-트립토판의 가용화 조성물 및 이를 이용한 제제
RU2289422C2 (ru) Фармацевтическая композиция на основе ноопепта
KR20130073288A (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
DD301037A5 (de) Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände